MALCOLM J VANDENBURG

PUBLICATIONS AND PRESENTATIONS

2023
CONTENTS

I. ANTIBIOTICS ................................................................. 5
   A. Publications .................................................................. 5
   B. Presentations to Learned Societies .............................. 5
   C. Presentations at Congresses and Symposia ................. 2
   D. Other Presentations .................................................. 2

II. RHEUMATOLOGY ........................................................... 3
    A. Publications ............................................................. 3
    B. Presentations to Learned Societies .............................. 4
    D. Other Presentations .................................................. 4

III. EFFECTS OF ANTIHYPERTENSIVE AGENTS ON PERIPHERAL VASCULAR PHYSIOLOGY AND SYMPTOMS ................ 5
     A. Publications ............................................................. 5
     B. Presentations to Learned Societies .............................. 5
     C. Presentations at Congresses and Symposia ................. 5
     D. Other Presentations .................................................. 6

IV. CONVERTING ENZYME INHIBITION ................................ 7
     A. Publications ............................................................. 7
     B. Presentations to Learned Societies .............................. 8
     C. Presentations at Congresses and Symposia ................. 9

V. CASE REPORTS ............................................................. 11
    A. Publications ............................................................. 11
    B. Presentations ............................................................. 11

VII. GENERAL MEDICAL TOPICS ........................................ 12
     A. Publications ............................................................. 12
     B. Presentations to Learned Societies .............................. 12
     C. Presentations at Congresses and Symposia ................. 13

VIII. HYPERTENSION GENERAL ........................................ 14
      A. Publications ............................................................. 14
      B. Presentations to Learned Societies .............................. 14
      C. Presentations at Congresses and Symposia ................. 15

IX. EFFECT OF POTASSIUM ON ARRHYTHMIAS .................... 16
     A. Publications ............................................................. 16
     B. Presentations to Learned Societies .............................. 16
     C. Presentations at Congresses and Symposia ................. 16
     D. Other Presentations .................................................. 17

X. EFFECT OF POTASSIUM ON HYPERTENSION ....................... 18
     A. Publications ............................................................. 18
     C. Presentations at Congresses and Symposia ................. 18

XI. CLINICAL STUDIES ON MODUCREN ................................ 19
     A. Publications ............................................................. 19
XII. MAGNESIUM ................................................................. 20
   A. Publications .......................................................... 20
   B. Presentations to Learned Societies ................................ 20
XIII. TRIPLE THERAPY FOR HYPERTENSION ................................. 21
   A. Publications .......................................................... 21
   B. Presentations to Learned Societies ................................ 21
XIV. NEUROPEPTIDES ............................................................. 22
   A. Publications .......................................................... 22
   B. Presentations to Learned Societies ................................ 22
   C. Presentations to Congresses and Symposia ....................... 22
XV. RESEARCH METHODOLOGY .................................................. 23
   A. Publications .......................................................... 23
   B. Presentations to Learned Societies ................................ 25
   C. Presentations to Congresses and Symposia ....................... 25
   D. Courses ............................................................... 26
XVI. ISOSORBIDE MONONITRATE IN HEART FAILURE ...................... 29
   A. Publications .......................................................... 29
   B. Presentations to Learned Societies ................................ 29
   C. Presentations at Congresses and Symposia ....................... 31
XVII. QUALITY OF LIFE ............................................................. 32
   A. Publications .......................................................... 32
   B. Presentations to Learned Societies ................................ 32
   C. Presentations at Congresses and Symposia ....................... 33
XVIII. BRL 34915 ...................................................................... 34
   A. Publications .......................................................... 34
   B. Presentations to Learned Societies ................................ 34
IXX. ANGINA STUDIES .................................................................. 35
   A. Publications .......................................................... 35
   B. Presentations to Learned Societies ................................ 35
   C. Presentations at Congresses and Symposia ....................... 36
XX. PHARMACOKINETICS .............................................................. 37
   A. Publications .......................................................... 37
   B. Presentations to Learned Societies ................................ 37
   C. Presentations at Congresses and Symposia ....................... 37
XXII. GENERAL MEDICAL TOPICS .................................................. 38
   B. Presentations to Learned Societies ................................ 38
XXIII. ADVISORY BOARDS AND ACADEMIC REVIEWS .................... 39
XXIV. 1997 EDITORIAL ARTICLES .................................................. 40
   A. Scrip ........................................................................ 40
   B. Applied Clinical Trials ............................................... 40
   C. European Pharmaceutical Contractor ............................. 40
   F. Ham & High ............................................................ 41
   G. Sales Director .......................................................... 41
   H Training Officer ........................................................ 41
   I Pharmaceutical Marketing ............................................. 41
J. GMC Today ................................................................. 41
K. R&D Direction ............................................................ 41
L. Miscellaneous ............................................................. 42

XXV. PERSONAL DEVELOPMENT ........................................... 43
A. Publications ............................................................... 43
B. Presentations ............................................................. 43
C. Presentations to Congresses and Symposia ....................... 44
D. Other Presentations ................................................... 44

XXVI. SLEEP APNEA AND CARDIO VASCULAR MONITORING .... 45
A. Publications ............................................................... 45
B. Presentations ............................................................. 45
C. Presentations to Congresses and Symposia ....................... 45
D. Other Presentations ................................................... 45

XXVII. BMJ RAPID RESPONSES ............................................ 46
I. **ANTIBIOTICS**

### A. Publications

1. Deaney N, Vogel R, Robertson M, Slack RCB, VandenBurg MJ and Currie WJC
   'TREATMENT OF ACUTE URINARY TRACT INFECTION IN WOMEN WITH A SHORT COURSE OF NORFLOXACIN'
   *Practitioner* 1984: 228 p111-117

   'NORFLOXACIN, AMOXICILLIN, COTRIMOXAZOLE AND NALIDIXIC ACID - AN OVERVIEW OF THREE AND SEVEN DAY THERAPY STUDIES IN THE TREATMENT OF URINARY TRACT INFECTION'
   *Journal of Antimicrobial Chemotherapy* 1984: 13 p113-120

3. Deaney N, Vogel R, VandenBurg MJ and Currie WJC
   'NORFLOXACIN ACTIVITY AGAINST PSEUDOMONAS'
   *Practitioner* 1984: 228 p619

   'IS ORAL CEFUROXIME AXETIL SUITABLE FOR THE TREATMENT OF UNIDENTIFIED BACTERIAL INFECTION OF SKIN AND SOFT TISSUE'
   *British Journal of Clinical Practice* 1987: 41 p954-956

   'EFFICACY AND TOLERABILITY OF CEFUROXIME AXETIL IN PATIENTS WITH UPPER RESPIRATORY TRACT INFECTIONS'
   *Current Medical Research and Opinion* 1987: 10 p555-561

   'QUALITY OF LIFE OF PATIENTS WITH INFECTION AND THE EFFECT OF TREATMENT WITH ORAL CEFUROXIME AXETIL'
   *Supplement to Practitioner* 1988 - A profile of cefuroxime axetil, 1988: p29-31

   'AN ASSESSMENT OF THE CLINICAL EFFICACY IN GENERAL PRACTICE OF CEFUROXIME AXETIL WHEN USED IN THE MANAGEMENT OF UNIDENTIFIED INFECTIONS OF THE LOWER RESPIRATORY TRACT'
   *British Journal of Clinical Practice* 1987: 41 p991-994

   'SUSCEPTIBILITY OF AEROBIC AND FACULTATIVE ANAEROBIC ORGANISMS TO IMPENEM'

### B. Presentations to Learned Societies

   'THREE DAYS OF NORFLOXACIN COMPARED WITH SEVEN DAYS OF AMOXICILLIN OR COTRIMOXAZOLE IN THE MANAGEMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS'
   European Society Clinical Microbiology, Bologna 1983

2. VandenBurg MJ, Wight LJ and Potter CE
   'MICROBIOLOGICAL EFFECTIVENESS OF CEFUROXIME AXETIL (CAE) IN URINARY TRACT INFECTIONS PRESENTING TO THE GENERAL PRACTITIONER'
   British Pharmacological Society 1990
   *British Journal of Clinical Pharmacology* 1990: 29 p636
C. **Presentations at Congresses and Symposia**

1. Wight LJ, VandenBurg MJ, Kelsey M
   'BACTERIOLOGICAL OUTCOME OF INFECTIONS TREATED WITH ORAL CEFUROXIME AXETIL IN GENERAL PRACTICE'
   Sixth Mediterranean Congress of Chemotherapy, Italy 1988
   Mediterranean Society of Chemotherapy, 1988: p258 - Abstract 313

2. Wight LJ, VandenBurg MJ, Griffiths GK
   'QUALITY OF LIFE OF PATIENTS WITH INFECTIONS AND THE EFFECT OF TREATMENT WITH CEFUROXIME AXETIL'
   A Profile of Cefuroxime Axetil in General Practice - Royal College of Physicians, London 1988: p41 Abstracts Book

   'THE TREATMENT OF STREPTOCOCCAL PHARYNGITIS WITH CLARITHROMYCIN'
   IV World Conference on Clinical Pharmacology & Therapeutics, Heidelberg 1989

   'MICROBIOLOGICAL PROFILE OF CLARITHROMYCIN'
   IV World Conference on Clinical Pharmacology & Therapeutics, Heidelberg 1989:

   'SKIN AND SOFT TISSUE INFECTIONS TREATED WITH CLARITHROMYCIN'
   IV World Conference on Clinical Pharmacology & Therapeutics, Heidelberg 1989

   'CLARITHROMYCIN IN THE TREATMENT OF BRONCHITIS'
   IV World Conference on Clinical Pharmacology & Therapeutics, Heidelberg, July 1989

   LOW RESISTANCE OF LOWER RESPIRATORY TRACT (LRTI) PATHOGENS TO CEFUROXIME AXETIL

D. **Other Presentations**

1. VandenBurg MJ
   'ZINNAT, THE MEDICAL SCENE'
   Success unlimited - Glaxo national sales conference, 1987: 1
II. RHEUMATOLOGY

A. Publications

   'A DOUBLE BLIND COMPARISON OF OSMOSIN, BENOXAPROFEN AND PLACEBO IN THE TREATMENT OF OSTEOARTHRITIS'
   Current Medical Research and Opinion 1983: 8 p90-98

2. Young A, Rodriguez C, VandenBurg MJ and Currie WJC
   'OSMOSIN IN RHEUMATOID ARTHRITIS: INTERIM RESULTS'
   Current Medical Research and Opinion 1983: 8 p109-112

3. VandenBurg MJ and Currie WJC
   'RECOMMENDED DOSE OF OSMOSIN'

   'SULINDAC VERSUS IBUPROFEN IN SPRAINS AND STRAINS'
   British Journal Sports Medicine 1984: 18 p30-33

5. Walker JW, VandenBurg MJ and Currie WJC
   'DIFFERENTIAL EFFICACY OF TWO NON-Steroidal ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF SPORTS INJURIES'
   Current Medical Research and Opinion 1984: 9 p119-123

6. Currie WJC, VandenBurg MJ, Janke PG and Diggins JB
   'SYMPTOMATIC OSTEOARTHRITIS IN THE ELDERLY: MULTICENTRE COMPARATIVE STUDY OF SULINDAC AND IBUPROFEN'
   British Journal of Clinical Practice 1984: 38 p176-181

7. VandenBurg MJ, Currie WJC and Mann SG
   'DIFFERENTIAL EFFECTS OF TWO NON-Steroidal ANTI-INFLAMMATORY DRUGS ON THE PLASMA UREA OF ELDERLY PATIENTS WITH OSTEOARTHRITIS: A MULTICENTRE STUDY'
   British Journal of Clinical Practice 1984: 38 p403-406

   'THE EFFECT OF NON-Steroidal ANTI-INFLAMMATORY THERAPY ON PLASMA NEUROPEPTIDE CONCENTRATIONS IN PATIENTS WITH OSTEOARTHRITIS'
   British Journal of Rheumatology 1985: 24 p46-52

9. Tamrazians S and VandenBurg MJ
   'SULINDAC: NO ADVERSE RENAL EFFECTS'
   Geriatric Medicine 1985: 15 p39

10. Mistry CD, Lote CJ, Gokal R, Currie WJC, VandenBurg MJ and Mallick NP
    'EFFECTS OF SULINDAC ON RENAL FUNCTION AND PROSTAGLANDIN SYNTHESIS IN PATIENTS WITH MODERATE CHRONIC RENAL INSUFFICIENCY'
    Clinical Science 1986: 70 p501-505
B. **Presentations to Learned Societies**

1. Currie WJC, Mann SG and VandenBurg MJ  
   'DIFFERENTIAL EFFECTS OF NON-Steroidal ANTI-INFLAMMATORY DRUGS ON RENAL FUNCTION IN THE ELDERLY'  
   Medical Research Society, Southampton, 1983  
   Clinical Science 1983: 65 p58p-59p

   'METHODS OF ASSESSING PAIN IN CLINICAL TRIALS'  
   Medical Research Society, London 1984  
   Clinical Science 1984: 66 p78

D. **Other Presentations**

1. Mann SG, VandenBurg MJ, Currie WJC, Bouchier-Hayes T and Hope K  
   'A PLACEBO CONTROLLED EVALUATION OF A TOPICALLY APPLIED GEL CONTAINING INDOMETHACIN IN THE TREATMENT OF ACUTE SPORTS INJURIES'  

   'EFFECTS OF NON-STEROIDALS ON THE GASTRIC MUCOSA - A GASTROSCOPIC STUDY IN OSTEOARTHRITIS'  

   'A PLACEBO CONTROLLED EVALUATION OF A TOPICALLY APPLIED GEL CONTAINING INDOMETHACIN IN THE TREATMENT OF ACUTE SPORTS INJURIES'  
   Progress in Rheumatology II 1984: p255-258  
   Edited Israel Machtey, Published Rheumatology Service, Hasharon Hospital, Petah-Tiqva, Israel

   'PAIN ASSESSMENT IN THE ELDERLY PATIENT'  
III. EFFECTS OF ANTIHYPERTENSIVE AGENTS ON PERIPHERAL VASCULAR PHYSIOLOGY AND SYMPTOMS

A. Publications

1. VandenBurg MJ, Condon C and Ledingham JM
   ‘A COMPARISON OF THE EFFECTS OF PROPRANOLOL AND OXPRENOLOL ON FOREARM BLOOD FLOW AND SKIN TEMPERATURE’

2. VandenBurg MJ
   ‘THE ACUTE AND CHRONIC EFFECT OF OXPRENOLOL AND PROPRANOLOL ON PERIPHERAL BLOODFLOW IN HYPERTENSIVE PATIENTS’
   British Journal of Clinical Pharmacology 1982: 14 p733-737

3. VandenBurg MJ, Cooper WD, Woollard ML and Currie WJC
   ‘REDUCED PERIPHERAL SYMPTOMS IN ELDERLY PATIENTS TREATED WITH ALPHA-METHYLDOPA - A COMPARISON WITH PROPRANOLOL’
   British Journal of Clinical Pharmacology 1984: 26 p325-329

4. VandenBurg MJ, Evans SJW, Cooper WD, Bradshaw F and Currie WJC
   ‘IS THE FEELING OF COLD EXTREMITIES EXPERIENCED BY HYPERTENSIVE PATIENTS DUE TO THEIR DISEASE OR THEIR TREATMENT?’
   European Journal of Clinical Pharmacology 1984: 27 p47-49

5. Walley T, Tsao Y, Scott A, Mackay EM, VandenBurg MJ and Breckenridge A
   ‘EFFECTS OF DILEVALOL (R,R-LABETALOL) COMPARED WITH NIFEDIPINE ON HEART RATE, BLOOD PRESSURE AND MUSCLE BLOOD FLOW AT REST AND ON EXERCISE IN HYPERTENSIVE PATIENTS.’
   British Journal of Clinical Pharmacology 1993: 35 p623-628

B. Presentations to Learned Societies

1. VandenBurg MJ, Cooper WD, Currie WJC, Evans SW and Bradshaw F
   ‘FACTORS INFLUENCING THE REPORTING OF COLD EXTREMITIES IN HYPERTENSIVE PATIENTS’
   Scientific Meeting of the British Hypertension Society 1983
   Journal of Hypertension 1984: 1 p319-320

   ‘EFFECTS OF DILEVALOL, PROPRANOLOL AND PLACEBO ON RETINAL BLOOD FLOW, BLOOD PRESSURE AND HEART RATE: A DOUBLE-BLIND STUDY’
   Fourth Meeting on Hypertension, Milan 1989
   Journal of Human Hypertension 1990: 4 p63

3. Walley T, Tsao Y, Scott A, Mackay EM, VandenBurg MJ and Breckenridge A
   ‘EFFECTS OF DILEVALOL AND NIFEDIPINE ON HEART RATE, BLOOD PRESSURE AND MUSCLE BLOOD FLOW BEFORE AND AFTER EXERCISE IN HYPERTENSIVE PATIENTS’
   British Pharmacology Society 1992
   British Journal of Clinical Pharmacologists 1993: 33 p86

C. Presentations at Congresses and Symposia
   'EFFECTS OF DILEVALOL, PROPRANOLOL AND PLACEBO ON RETINAL BLOOD FLOW, BLOOD PRESSURE AND HEART RATE: A DOUBLE-BLIND STUDY’
   Satellite of Fourth European Meeting on Hypertension, Monte Carlo 1989
   Journal of Hypertension 1990: 4 p63

D. Other Presentations

1. VandenBurg MJ
   'BETA-BLOCKADE AND PERIPHERAL BLOOD FLOW’
   Junior Cardiac Club Symposium, Reykjavik 1979

2. VandenBurg MJ
   'PERIPHERAL BLOOD FLOW AND BETA-BLOCKADE - IS IT IMPORTANT?’
   The Hypertension Society 1981
IV. CONVERTING ENZYME INHIBITION

A. Publications

1. VandenBurg MJ
   ‘CONVERTING ENZYME INHIBITOR’
   Medical Annual 1978: p306-308
   Editors Scott & Frazer, published by John Wright, Bristol

2. VandenBurg MJ, Sharman VL, Morton JJ, Williams GH and March FP
   ‘HORMONAL AND BLOOD PRESSURE CHANGES DURING CONVERTING ENZYME INHIBITION BY TEPROTIDE’

3. VandenBurg MJ, Holly JMP, Goodwin FJ, Sharman VL and Marsh FP
   ‘THE EFFECT OF CAPTOPRIL AND PROPRANOLOL ON THE RESPONSES TO POSTURE AND ISOMETRIC EXERCISE IN PATIENTS WITH ESSENTIAL HYPERTENSION’

4. U K Multicentre Study Group
   ‘ENALAPRIL IN ESSENTIAL HYPERTENSION: A COMPARATIVE STUDY WITH PROPRANOLOL’
   British Journal of Clinical Pharmacology 1984: 18 p51-56

   ‘ENALAPRIL IN MODERATE TO SEVERE HYPERTENSION: A COMPARISON WITH ATENOLOL’
   British Journal of Clinical Pharmacology 1986: 21 p489-495

   ‘ENALAPRIL IN THE TREATMENT OF HYPERTENSION ASSOCIATED WITH IMPAIRED RENAL FUNCTION’
   Journal of Hypertension 1985: 3 p471-474

   ‘PHARMACOKINETICS OF ENALAPRIL IN NORMAL SUBJECTS AND PATIENTS WITH RENAL IMPAIRMENT’
   British Journal of Clinical Pharmacology 1986: 21 p63-69

8. VandenBurg MJ, Morris F, Marks CE, Kelly JG, Dewes IM and Stephens JD
   ‘A STUDY OF THE POTENTIAL PHARMACOKINETIC INTERACTION OF LISINOPRIL AND DIGOXIN IN NORMAL VOLUNTEERS’
   Xenobiotica 1988: 18 p1179-1184

   ‘A COMPARISON OF SINGLE DOSES OF LISINOPRIL AND ENALAPRIL IN HYPERTENSION’
   Journal of Human Hypertension; Ace Inhibition - the Next Decade 1989: 3 p35-39

    THE PHARMACOKINETICS OF PERINDOPRIL AND ITS EFFECTS ON SERUM ANGIOTENSIN CONVERTING ENZYME activity IN HYPERTENSIVE PATIENTS WITH CHRONIC RENAL FAILURE

11. VandenBurg MJ, Mackay EM, Dewes IM, Pullan TR and Brugier S
    ‘DOSE FINDING STUDIES WITH IMIDAPRIL - A NEW ACE INHIBITOR’
12. Dews I and VandenBurg MJ
‘A 24 WEEK DOSE-TITRATION STUDY OF THE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR IMIDAPRIL IN THE TREATMENT OF MILD-TO-MODERATE ESSENTIAL HYPERTENSION IN THE ELDERLY’
The Journal of International Medical Research, 2001; 29, p100-107

13. Dews I and VandenBurg MJ
‘A 52 WEEK, OPEN LABEL, DOSE-TITRATION SAFETY STUDY OF IMIDAPRIL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION’

B. Presentations to Learned Societies

‘THE EFFECT OF TREATMENT WITH CAPTOPRIL FOR FOUR WEEKS ON BLOOD PRESSURE, HEART RATE AND PLASMA NORADRENALINE AT REST, ON STANDING AND SITTING AND AFTER ISOMETRIC EXERCISE’
Medical Research Society 1981
Clinical Science 1981: 61 p36

‘ENALAPRIL AND PROPRANOLOL IN ESSENTIAL HYPERTENSION: A DOUBLE BLIND COMPARATIVE STUDY’
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 17 p606

‘HAEMODYNAMIC EFFECTS OF INTRAVENOUS ENALAPRILIC ACID (MK422) IN PATIENTS WITH CORONARY ARTERY DISEASE’
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 17 p629

‘THE PHARMACOKINETIC PROFILE OF ENALAPRILAT IN NORMAL SUBJECTS AND PATIENTS WITH RENAL IMPAIRMENT’
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 18 p284

‘A COMPARATIVE STUDY OF ENALAPRIL AND ATENOLOL IN MODERATE TO SEVERE HYPERTENSION’
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 18 p292

‘EFFECT OF CONVERTING ENZYME INHIBITION ON THE INCREASE IN SERUM POTASSIUM ASSOCIATED WITH EXERCISE’
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1985: 19 p134

7. Morris FP, Tamrazians S, Marks CE, Kelly J, Stephens JD and VandenBurg MJ
‘AN ACUTE PHARMACOKINETIC STUDY OF THE POTENTIAL INTERACTION OF LISINOPRIL AND DIGOXIN IN NORMAL VOLUNTEERS’
British Pharmacological Society 1985
British Journal of Clinical Pharmacology 1985: 20 p281-282

Raman G, VandenBurg MJ and Woolard ML
'ENALAPRIL IN THE TREATMENT OF HYPERTENSION ASSOCIATED WITH IMPAIRED RENAL FUNCTION'
British Pharmacological Society 1985
British Journal of Clinical Pharmacology 1985: 20 p280-281

'ENALAPRIL IN THE TREATMENT OF HYPERTENSION ASSOCIATED WITH IMPAIRED RENAL FUNCTION'
Second European Meeting on Hypertension, Milan, 1985: Abstract 109

'CHRONIC DOSE PHARMACOKINETICS OF ENALAPRIL IN RENAL IMPAIRMENT'
British Pharmacological Society 1985
British Journal of Clinical Pharmacology 1985: 20 p264-265

'DISPARATE OBJECTIVE AND SUBJECTIVE ASSESSMENTS IN MILD TO MODERATE CONGESTIVE HEART FAILURE: RESULTS FROM A DOUBLE-BLIND STUDY OF LISINOPRIL VERSUS PLACEBO'
Medical Research Society 1987: 74 p63 - Abstract 234

'EFFECTS OF LISINOPRIL ON SYMPTOMS, EXERCISE TOLERANCE AND NEUROPEPTIDES IN MILD TO MODERATE HEART FAILURE'
Fifth joint meeting of the working groups of the European Society of Cardiology. Santiago De Compostella 1987

'THE EFFECTS OF LISINOPRIL ON DIGOXIN PHARMACOKINETICS IN PATIENTS WITH CONGESTIVE HEART FAILURE'
British Pharmacological Society 1988
The British Journal of Clinical Pharmacology 1988: 25 p656

'PHARMACOKINETICS OF PERINDOPRIL AND PERINDOPRILAT IN HYPERTENSIVE PATIENTS WITH RENAL IMPAIRMENT'
British Pharmacological Society 1990
British Journal of Clinical Pharmacology 1990: 29 p647

15. Zeisser P, Mackay EM, VandenBurg MJ and Brugier S
RELATION DOSE-EFFECT ETUDE D'UN NOUVEL INHIBITEUR DE L'ENZYME DE CONVERSION

C. Presentations at Congresses and Symposia

'COMPARISON BETWEEN CAPTOPRIL AND PROPRANOLOL IN ESSENTIAL HYPERTENSION'

2. VandenBurg MJ, Parfrey PS, Sharman VL, Wright P, Condon K, Goodwin FJ and Marsh FP
'THE EFFECT OF CAPTOPRIL ON THE RESPONSE TO ISOMETRIC EXERCISE'
International Symposium on the ACE Inhibitor (Captopril) 1980: p80 Hospitalet de Llobregat, Barcelona - Edited by J. Alsina

3. VandenBurg MJ
'ORALLY ACTIVE ANGIOTENSIN-CONVERTING ENZYME INHIBITOR (SQ 14,225) AS A TREATMENT FOR ESSENTIAL HYPERTENSION'
British Journal of Clinical Pharmacology 1979: 7 Suppl. 2 p211S

'COMPARISON OF LISINOPRIL AND ENALAPRIL IN HYPERTENSION'
Scientific Programme
Ace Inhibitors - The Next Decade, Cannes 1988: p38 - Abstracts Book

'Lisinopril versus Enalapril: single doses in hypertension'
International Symposium on Ace Inhibitors 1989: Abstract F074
V. CASE REPORTS

A. Publications

1. VandenBurg MJ, Sharman L and Marsh F
   'Prolonged treatment of high renin hypertension with a converting enzyme inhibitor'
   British Medical Journal 1978: 407 p866-867

2. Parfrey PS, Clement M, VandenBurg MJ and Wright P
   'Captopril-induced pemphigus'
   British Medical Journal 1980: 281 p194

   'Hepatitis associated with captopril treatment'
   British Journal of Clinical Pharmacology 1981: 11 p105-106

4. Swash M, Schwartz MS, VandenBurg MJ and Pollock DJ
   'Myopathy in Whipple's disease'
   GUT 1977: 18 p800-804

5. Rae S, VandenBurg MJ and Scholtz CL
   'Aortic regurgitation in Behcets disease'
   Postgraduate Medical Journal 1980: 56 p438-439

6. VandenBurg MJ and Foale R
   'Diastolic murmur in patients with end stage renal disease'
   British Heart Journal 1980: 43 p713

   'Late presentation of acquired VSD in an elderly man'
   Clinical Notes On-Line 1986: L p151

8. Hounslow NJ, VandenBurg MJ and Stephens JD
   'Constipation due to flecainide in a man with treated hypothyroidism'
   Clinical Notes On-Line 1986: L p170

B. Presentations

1. M VandenBurg. London, UK
   Ethics in Ophthalmic Clinical Trials
   'Ethics in Clinical Research – The Physician’s Perspective’ and ‘Panel Discussion’
   Presented at meeting - 5th International Symposium on Ocular Pharmacology and Therapeutics ISOPT
   Montecarlo. Monaco
   11-14 March 2004
VII. GENERAL MEDICAL TOPICS

A. Publications

   ‘IMPAIRED RESPONSE OF PLASMA RENIN ACTIVITY TO TILTING AFTER RENAL TRANSPLANTATION’
   Clinical Science 1981: 61 p69-73

2. VandenBurg MJ, Barnes MN, Goodwin FJ and Marsh FP
   ‘CONTRACEPTIVE PRACTICES OF, AND ADVICE RECEIVED BY, FEMALE PATIENTS BEING TREATED BY
   HAEMODIALYSIS’
   British Journal of Family Planning 1981: 7 p77-80

3. VandenBurg MJ and Cooper WD
   ‘CAN DRUGS PREVENT RECURRENT MYOCARDIAL INFARCTION?’
   Journal of Clinical and Hospital Pharmacy 1982: 7 p209-212

   WJC
   ‘A LASER FLASH PHOTOLYSIS AND PULSE RADIOLYSIS STUDY OF AMILORIDE IN AQUEOUS AND ALCOHOLIC
   SOLUTION’

5. ‘EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY
   REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL’
   a) The Lancet 1988: 1 p545-549
   b) The Lancet 1990: 335 p427-431

6. Dews IM, Marks CE, VandenBurg MJ and Stephens JD
   ‘PREVENTION OF ATHEROSCLEROTIC COMPLICATIONS WITH KETANSERIN’
   British Medical Journal 1989: 298 p752

   ‘THE EFFECTS OF KETANSERIN ON VENTRICULAR ECTOPIC ACTIVITY IN HUMANS’
   Cardiovascular Drugs and Therapy 1990: 4 p93-95

8. Rumfitt IW, Norris RJN, Dews IM and VandenBurg MJ
   ‘AN ASSESSMENT OF THE EFFECTS OF CELIPROLOL ON SERUM LIPOPROTEIN CONCENTRATIONS AND THEIR
   IMPLICATIONS FOR THE PREVENTION OF CORONARY ARTERY DISEASE’
   J. Drug Dev. 1991: 4(3); p117-123

B. Presentations to Learned Societies

1. Silman A and VandenBurg MJ
   ‘PEPTIC ULCER PERFORATION IN ENGLAND AND WALES: NOT A DIMINISHING PROBLEM’
   Conference on Community Health 1984
   Journal of Epid and Community Health 1985: 39 p94

2. VandenBurg MJ, Cooper WD and Kimber GR
   ‘DOES THE LACK OF PATIENT KNOWLEDGE ABOUT GLYCERYL TRINITRATE LIMIT THE USEFULNESS OF THE
   DRUG?’
   British Pharmacological Society 1985
   British Journal of Clinical Pharmacology 1985: 20 p246-246

3. Tamrazians S, Booton P, Wiseman Wan Thai, Cooper WD, Stephens JD and VandenBurg MJ
   ‘WHICH ELDERLY PATIENTS IN SUSTAINED ATRIAL FIBRILLATION ARE GERIATRICIANS ANTICOAGULATING?’
   British Pharmacological Society 1985
   British Journal of Clinical Pharmacology 1986: 21 p599-600
4. VandenBurg MJ
'THE ROLES OF THE PHYSICIAN'
British Institute of Regulatory Affairs 1986. Effective Use of the CTX Scheme A One Day Meeting and Workshop on Practical Issues.

5. Hounslow N, Wiseman WT, Stephens JD, Marks CE and VandenBurg MJ
'PILOT STUDY TO ASSESS THE USE OF VISUAL ANALOGUE SCALES IN THE ASSESSMENT OF ANGINA'
Medical Research Society 1987
Clinical Science 1987: 72 p10

'AN OPEN STUDY TO ASSESS THE EFFECT OF NITROLINGUAL SPRAY ON HAEMODYNAMIC PARAMETERS IN PATIENTS WITH CONGESTIVE HEART FAILURE'
British Journal of Clinical Pharmacology 1992: 33 (2) p223

C. Presentations at Congresses and Symposia

'DIFFERENTIAL EFFECT OF TWO DOSES OF ENCAINIDE ON VENTRICULAR ECTOPIC ACTIVITY'
International Symposium 'Ventricular Tachycardias', Vittel, France 1986 - Abstracts Book p71

2. Robinson PJ, Al-Khawaja IM, Marks CE, VandenBurg MJ and Stephens JD
'A COMPARISON OF THE HAEMODYNAMIC EFFECTS OF DOPEXAMINE HYDROCHLORIDE AND DOPAMINE IN PATIENTS WITH CHRONIC CARDIAC FAILURE'

'EFFECTS OF DILEVALOL, PROPRANOLOL AND PLACEBO ON RETINAL BLOOD FLOW, BLOOD PRESSURE AND HEART RATE: A DOUBLE-BLIND STUDY'
Current Topics and Future Trends in Hypertension - Kirby-warrick
Journal of Human Hypertension 1990: 4 p63

4. Vandenburg MJ and Foale R
'DRUG ABUSE, CONGESTIVE CARDIOMYOPATHY AND THE ECG'

5. VandenBurg MJ
'INFORMED CONSENT, LEGAL LIABILITY AND INDEMNITY'
Joint Meeting of the Society of Pharmaceutical Medicine and The British Branch of the International League Against Epilepsy
Institute of Child Health 1988
VIII. HYPERTENSION GENERAL

A. Publications

1. VandenBurg MJ
   "BETA-BLOCKERS AND PROSTAGLANDINS"
   *Lancet* 1977: 2 p1184

2. Cooper WD, Currie WJC and VandenBurg MJ
   "PHYSICIANS' INSTRUCTIONS IN THE TREATMENT OF HYPERTENSION"
   *British Journal of 1983:* 37 p99-103

3. Ritchie LD, Harrington LT, MacGregor AR and VandenBurg MJ
   "NIFEDIPINE AS LOW-DOSE MONOTHERAPY FOR ESSENTIAL HYPERTENSION: A PRIMARY CARE STUDY"
   *Cardiovascular Drugs and Therapy* 1989: 3 p341

   "A RANDOMIZED CROSSOVER STUDY OF THE BLOOD PRESSURE EFFECTS OF TOBACCO AND NON-TOBACCO CIGARETTES"
   *Journal of Hypertension* 1991: 9 (6) S120-121

   "MORNING VERSUS EVENING DOsing OF SUSTAINED-RELEASE VERAPAMIL IN MILD-TO-MODERATE HYPERTENSION"
   *Research and Clinical Forums:* 12 (2) p71-78

   "QUALITY OF LIFE AND COGNITIVE FUNCTION WITH A DIURETIC COMPARED WITH A BETA BLOCKER: A RANDOMIZED CONTROLLED TRIAL OF BENDROFLUAZIDE VERSUS DILEVALOL IN ELDERLY HYPERTENSIVE PATIENTS"
   *Cardiology in the Elderly,* April 1995: 3 p139

B. Presentations to Learned Societies

1. Cooper WD, VandenBurg MJ and Currie WJC
   "DIETARY SALT RESTRICTION AS AN ADJUNCT TO DRUG TREATMENT IN ESSENTIAL HYPERTENSION"
   *Medical Research Society 1983*
   *Clinical Science* 1983: 64 p56

2. VandenBurg MJ, Currie WJC and Cooper WD
   "FACTORS INFLUENCING THE RESPONSE TO ANTIHYPERTENSIVE THERAPY"
   *Medical Research Society 1983*
   *Clinical Science* 1983: 65 p30

3. Young JH, VandenBurg MJ, Cooper WD and Currie WJC
   "DOES THE TIME OF ADMINISTRATION OF ANTIHYPERTENSIVE DRUGS AFFECT THEIR RESPONSE AND SYMPTOM PROFILE?"
   *British Pharmacological Society 1984*
   *British Journal of Clinical Pharmacology* 1984: 18 p293-294

   "AGE DOES NOT ALTER THE EFFECT OF LOW DOSE NIFEDIPINE THERAPY",
   *Cardiovascular Drugs and Therapy* 1987: 4 p304
'MORNING VERSUS EVENING DOSING OF SLOW-RELEASE VERAPAMIL IN MILD TO MODERATE HYPERTENSION'
British Pharmacology Society 1990
British Journal of Clinical Pharmacology 1990: 30 p338-339

'A DOUBLE-BLIND GENERAL PRACTICE BASED COMPARATIVE STUDY OF SLOW RELEASE VERAPAMIL WITH ATENOLOL IN PATIENTS WITH MILD TO MODERATE HYPERTENSION'
British Pharmacological Society 1990
British Journal of Clinical Pharmacology 1990: 30 p339-340

7. Dews IM, VandenBurg MJ and Pullan TR
'BLOOD PRESSURE EFFECTS OF TOBACCO AND NON-TOBACCO CIGARETTES'
Fifth Scientific Meeting of the European Society of Hypertension, Milan 1991.

C. Presentations at Congress and Symposia

1. Ritchie LD, VandenBurg MJ, Harrington L and MacGregor A
'LOW DOSE, SLOW RELEASE NIFEDIPINE IN HYPERTENSION: A MULTICENTRE PRIMARY CARE STUDY'.
Calcium Antagonists in Hypertension 25th Anniversary International Symposium, Basel 1988

2. Gould SE, VandenBurg MJ, Dews IM, Marks CE and Stephens JD
'EFFECT OF KETANSERIN ON VENTRICULAR ECTOPIC ACTIVITY IN MAN'
Serotonin and Vascular Disease Satellite Symposium to the Fourth European Meeting on Hypertension, Milan 1989: p40

'NITRENDIPINE OR HYDRAZINE AS THIRD LINE TREATMENT FOR HYPERTENSION'

4. VandenBurg MJ, Dews IM, Marks CE, Stephens JD, and Gould SE
'EFFECT OF KETANSERIN ON VENTRICULAR ECTOPIC ACTIVITY IN MAN'
International Symposium on Serotonin from Cell Biology to Pharmacology and Therapeutics; Florence 1989: p157 - Abstracts book
IX. **EFFECT OF POTASSIUM ON ARRHYTHMIAS**

A. **Publications**

1. Wilkins J, Kendall M, VandenBurg MJ and Currie WJC
   ‘IS DIURETIC-INDUCED HYPOKALAEMIA CLINICALLY IMPORTANT’
   *British Journal of Hospital and Clinical Pharmacy* 1983: 8 p367-377

2. Cooper WD, VandenBurg MJ, Kuan P and Reuben SR
   ‘CARDIAC ARRHYTHMIAS FOLLOWING ACUTE MYOCARDIAL INFARCTION: ASSOCIATIONS WITH THE SERUM POTASSIUM LEVEL AND PRIOR DIURETIC THERAPY’
   *European Heart Journal* 1984: 5 p464-469

3. VandenBurg MJ and Currie WJC
   ‘MILD HYPOKALAEMIA DOES APPEAR TO BE ASSOCIATED WITH CARDIAC ARRHYTHMIAS’
   *Practitioner* 1984: 229 p777-779

4. Cooper WD and VandenBurg MJ
   ‘RELATIONSHIP BETWEEN INITIAL SERUM POTASSIUM VALUES AND CARDIAC ARRHYTHMIAS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION’

B. **Presentations to Learned Societies**

   ‘POTASSIUM AND CARDIAC ARRHYTHMIAS IN ELDERLY PATIENTS TREATED WITH DIURETICS’
   Medical Research Society 1983
   *Clinical Science* 1983: 65 p47

2. Cooper WD, Reuben S, VandenBurg MJ, Thomas RD and Currie WJC
   ‘HYPOKALAEMIA AND ACUTE MYOCARDIAL INFARCTION: THE ROLE OF DIURETIC THERAPY’
   Third Joint Meeting of the Working Groups of the European Society of Cardiology, Spa, Belgium 1983
   *European Heart Journal* 1983: 4 p6

3. VandenBurg MJ
   ‘RELATIONSHIP BETWEEN INITIAL SERUM POTASSIUM VALUES AND CARDIAC ARRHYTHMIAS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION’
   International Symposium, Potassium in Cardiovascular and Renal Medicine, The John Hopkins University School of Medicine in co-operation with the National High Blood Pressure Education Program, Baltimore, 1984

4. VandenBurg MJ
   ‘CARDIAC ARRHYTHMIA AND ITS RELATIONSHIP TO HYPOKALEMIA’
   Pakistan Society of Physicians Biennial Convention, Pakistan 1987
   *Doctor International* 1987: 8 p6

C. **Presentations at Congresses and Symposia**

   ‘CARDIAC ARRHYTHMIAS FOLLOWING ACUTE MYOCARDIAL INFARCTION: ASSOCIATIONS WITH THE SERUM POTASSIUM LEVEL AND PRIOR DIURETIC THERAPY’
   International Symposium on Potassium, Blood Pressure and Cardiovascular Disease, Capri 1983: p32
   Potassium, Blood Pressure and Cardiovascular Disease (Posters)
   Editor: A Zanchetti. Excerpta Medica, Amsterdam, p7-9
2. Cooper WD, VandenBurg MJ and Currie WJC
'THE ASSOCIATION BETWEEN DIURETICS AND HYPOKALAEMIA IN ACUTE MYOCARDIAL INFARCTION'
International Symposium on Potassium, Blood Pressure and Cardiovascular Disease, Capri 1983: p33
Potassium, Blood Pressure and Cardiovascular Disease (Posters)
Editor: A Zanchetti. Excerpta Medica, Amsterdam, p10-11

3. VandenBurg MJ, McCarthy S, Cooper WD, McCarthy G and Currie WJC
'THE EFFECT OF DIURETICS ON THE POTASSIUM STATUS AND FREQUENCY OF CARDIAC ARRHYTHMIAS IN ELDERLY PATIENTS'
International Symposium on Potassium, Blood Pressure and Cardiovascular Disease, Capri 1983
Potassium, Blood Pressure and Cardiovascular Disease (Posters)
Editor: A Zanchetti. Excerpta Medica, Amsterdam, p68-71

4. Reuben SR, VandenBurg MJ and Cooper WD
'THE INFLUENCE OF PRIOR DIURETIC THERAPY ON THE INCIDENCE OF EARLY HYPOKALAEMIA AND CARDIAC ARRHYTHMIAS FOLLOWING ACUTE MYOCARDIAL INFARCTION'
First World Congress on Diuretics, Miami 1984
Organised by University of Pittsburgh Medical School

D. Other Presentations

1. VandenBurg MJ
'THE DANGERS OF HYPOKALAEMIA'
Our Pharmaceutical Heritage from Great Britain: The Texas State Society of the American College of General Practitioners, 1982

2. VandenBurg MJ
'HYPOKALAEMIA AND CARDIAC ARRHYTHMIAS'
Indian Medical Association, London 1985
X. EFFECT OF POTASSIUM ON HYPERTENSION

A. Publications

1. Holly JMP, Evans SJW, Goodwin FJ, VandenBurg MJ and Ledingham JM
   ‘RE-ANALYSIS OF DATA IN TWO LANCET PAPERS ON THE EFFECT OF DIETARY SODIUM AND POTASSIUM ON BLOOD PRESSURE’
   Lancet 1981: 2 p1384-1386

   ‘BLOOD PRESSURE AND HORMONAL CHANGES FOLLOWING ALTERATION IN DIETARY SODIUM AND POTASSIUM IN YOUNG MEN WITH AND WITHOUT A FAMILIAL PREDISPOSITION TO HYPERTENSION’
   Lancet 1981: 2 p113-117

   ‘BLOOD PRESSURE AND HORMONAL CHANGES FOLLOWING ALTERATION IN DIETARY SODIUM AND POTASSIUM IN MILD ESSENTIAL HYPERTENSION’
   Lancet 1981: 1 p59-63

C. Presentations at Congresses and Symposia

1. Currie WJC, Cooper WD and VandenBurg MJ
   ‘PLASMA POTASSIUM MAY INFLUENCE THE RESPONSE TO ANTIHYPERTENSIVE THERAPY’
   International Symposium on Potassium, Blood Pressure and Cardiovascular Disease, Capri 1983
   Potassium, Blood Pressure and Cardiovascular Disease (Posters)
   Editor: A Zanchetti. Excerpta Medica 1983, Amsterdam, p18-20
XI. CLINICAL STUDIES ON MODUCREN

A. Publications

1. VandenBurg MJ and Currie WJC
   'AN 8 WEEK STUDY TO COMPARE THE EFFECTS OF MODUCREN AND PROPRANOLOL IN PATIENTS WITH MILD TO MODERATE HYPERTENSION'
   Symposium 'Considerations in the Treatment of Hypertension' organised by Thomas Morson Pharmaceuticals 1982
   *International Medicine 1982: 4 p20-23*

2. Cooper WD, Parry E, Tait D, VandenBurg MJ and Currie WJC
   'MANAGEMENT OF UNCONTROLLED HYPERTENSION WITH MODUCREN: A STUDY IN GENERAL PRACTICE'
   *International Medicine 1982: 4 p44-47*

3. VandenBurg MJ, Isitt V, Wight LJ, Cooper WD and Currie WJC
   'A REVIEW OF SYMPTOMS REPORTED BY 5094 PATIENTS WITH ESSENTIAL HYPERTENSION TAKING MODUCREN FOR 3 MONTHS'
   Symposium 'Hypertension and Hypokalaemia: Cause for Concern', organised by Thomas Morson Pharmaceuticals 1982
   *International Medicine 1983: 5 p23-26*

4. Cooper WD, VandenBurg MJ and Currie WJC
   'THE ANTIHYPERTENSIVE EFFICACY OF MODUCREN IN 5094 PATIENTS TREATED IN GENERAL PRACTICE'
   *International Medicine 1983: 5 p47-52*

5. Barnes JN, Drew PJT, Skehan JD, Wright P and VandenBurg MJ
   'BIOCHEMICAL DISTURBANCES ASSOCIATED WITH HYDROCHLOROTHIAZIDE TREATMENT OF HYPERTENSION: EFFECT OF ADDING AMILODIRE PLUS TIMOLOL'
   *International Medicine 1983: 5 p12-15*

6. Currie WJC, VandenBurg MJ and Cooper WD
   'DO ELDERLY PATIENTS RESPOND DIFFERENTLY TO TREATMENT WITH MODUCREN?'
   *British Journal of Clinical Practice 1984: 38 p102-106*

7. VandenBurg MJ, Currie WJC and Cooper WD
   'THE USE OF A SINGLE COMBINATION TABLET CONTAINING A BETA-BLOCKER AND A DIURETIC IN PATIENTS UNCONTROLLED ON EITHER ALONE'
   *British Journal of Clinical Practice 1984: 38 p221-223*

8. Young JH, VandenBurg MJ and Isitt VI
   'COMPARISON OF MODUCREN GIVEN ONCE A DAY VERSUS TWICE A DAY IN MILD TO MODERATE HYPERTENSION'
   *Pharmatherapeutica 1984: 4 p64-68*
XII. MAGNESIUM

A. Publications

1. Barnes JN, Drew PJT, Skehan JD and VandenBurg MJ
   'DIURETIC ASSOCIATED HYPOMAGNESEAZMIA’
   *British Medical Journal 1983: 286 p146-147*

B. Presentations to Learned Societies

1. Robinson PJ, Morgan DB, Davidson C, Woolard ML and VandenBurg MJ
   'EFFECTS OF AMILORIDE AND SPIRONOLACTONE ON PLASMA MAGNESIUM IN FRUSEMIDE-TREATED PATIENTS WITH CARDIAC FAILURE’
   *British Pharmacological Society 1984*
   *British Journal of Clinical Pharmacology 1984: 18 p268*

   'SERUM MAGNESIUM IS UNAFFECTED BY ANGIOTENSIN CONVERTING ENZYME INHIBITION’
   *Medical Research Society, London, 1985*
   *Clinical Science 1985: 68 p77*
XIII. TRIPLE THERAPY FOR HYPERTENSION

A. Publications

1. Anonymous
   'WHEN TO USE ORAL VASODILATORS IN THE TREATMENT OF HYPERTENSION'
   The Consumers' Association
   Drugs and Therapeutics Bulletin 1979: 17 p57-59

2. Ahmad RA, Rogers HJ, VandenBurg MJ and Wright P
   'EFFECTS OF CONCURRENT ADMINISTRATION OF OTHER SUBSTRATES OF N-ACETYLTTRANSFERASE ON DAPSONE ACETYLATION'
   British Journal of Clinical Pharmacology 1981: 12 p83-86

3. VandenBurg MJ, Wright P, Holmes J, Rogers HJ and Ahmad RA
   'THE HYPOTENSIVE RESPONSE TO HYDRALAZINE IN TRIPLE THERAPY IS NOT RELATED TO ACETYLATOR PHENOTYPE'

4. VandenBurg MJ, Sharman L, Wright P, Drew P and Barnes J
   'HYDRALAZINE AND PRAZOSIN IN THE TREATMENT OF HYPERTENSION'
   British Journal of Clinical Pharmacology 1983: 16 p536-542

   'QUADRUPLE THERAPY FOR RESISTANT HYPERTENSION'
   British Journal of Clinical Practice 1985: 39 p17-19

B. Presentations to Learned Societies

1. Skehan JD, Arr SM and VandenBurg MJ
   'ATTENUATION OF HYDRALAZINE TACHYCARDIA BY METHYLDOPA'
   British Pharmacological Society 1984
   British Journal of Clinical Pharmacology 1984: 19 p134-135
XIV. NEUROPEPTIDES

A. Publications

1. VandenBurg MJ, Robinson PJ, Cooper WD and Currie WJC
'THE EFFECTS OF ENALAPRIL AND PROPRANOLOL ON BETA-ENDORPHIN LIKE RADIOIMMUNOREACTIVITY IN HYPERTENSIVE PATIENTS'
Clinical and Experimental Theory and Practice, 1984: 10 p2069-2072

'LOPINORIL ON CIRCULATING NEUROPEPTIDES IN ESSENTIAL HYPERTENSIVE PATIENTS.'

B. Presentations to Learned Societies

'THE EFFECT OF NON-STERoidal ANTI-INFLAMMATORY THERAPY ON PLASMA NEUROPEPTIDE CONCENTRATIONS IN PATIENTS WITH OSTEOARTHRITIS'
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 17 p628

2. VandenBurg MJ, Robinson PJ, Cooper WD and Currie WJC
'DOES BETA-BLOCKADE OR ANGIOTENSIN CONVERTING ENZYME INHIBITION ALTER PLASMA B ENDORPHINS?'
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1984: 18 p292-293

3. VandenBurg MJ, Robinson PJ, Cooper WD, Arr SM and Currie WJC
'THE EFFECT OF CONVERTING ENZYME INHIBITION ON PLASMA METENKEPHALINS AT REST AND ON EXERCISE'
British Pharmacological Society 1984
British Journal of Clinical Pharmacology 1985: 19 p567

'THE EFFECT OF LISINOPRIL ON CIRCULATING NEUROPEPTIDES IN ESSENTIAL HYPER TENSION PATIENTS'
Eleventh Scientific Meeting of ISH 1986, Satellite Symposium on Opioid Peptides and Blood Pressure Control, Bonn 1986
Zentralblatt Innere Medizin 1986: 337 p227
Published by Springer-Verlag, Berlin 1986

C. Presentations to Congresses and Symposia

1. VandenBurg MJ, Robinson PJ, Cooper WD and Currie WJC
'EFFECTS OF ENALAPRIL AND PROPRANOLOL ON BETA-ENDORPHIN-LIKE RADIOIMMUNOREACTIVITY IN HYPERTENSION PATIENTS'
Symposium on Neuropeptides and Blood Pressure Control, Heidelberg 1984: p54

2. Brandman S, Jenkins R, Mann SG and VandenBurg MJ
'THE EFFECT OF NON-STERoidal ANTI-INFLAMMATORY THERAPY ON PLASMA NEUROPEPTIDE CONCENTRATIONS IN PATIENTS WITH OSTEOARTHRITIS'
Progress in Rheumatology, 1984: 11 p267-271
Edited by Israel Machtey, Published by Rheumatology Service, Hasharon Hospital, Petah-Tiqva, Israel
XV. RESEARCH METHODOLOGY

A. Publications

1. VandenBurg MJ, Evans SJW, Kelly BJ, Bradshaw F, Currie WJC and Cooper WD
   'FACTORS AFFECTING THE REPORTING OF SYMPTOMS BY HYPERTENSIVE PATIENTS'
   Symposium on Enalapril 1984
   British Journal of Clinical Pharmacology 1984: 18 p189S-194S

   'DOES IT MATTER HOW VISUAL ANALOGUE SCALES ARE USED IN CLINICAL STUDIES?'
   Pharmaceutical Medicine 1984: 1 p47-52

3. VandenBurg MJ, Gerlis L, Nutley P
   'GOOD CLINICAL PRACTICE: A WAY TO BETTER DRUGS'
   British Medical Journal 1989: 299 p858

4. Nutley PG and VandenBurg MJ
   'THE SPREAD OF GOOD CLINICAL PRACTICE'
   Pharmaceutical Manufacturing International 1990: p49-51

5. Nutley PG and VandenBurg MJ
   'THE IDENTIFICATION OF FALSE CLINICAL DATA'
   Pharmaceutical Manufacturing International 1990: p53-55

6. VandenBurg MJ and Nutley PG
   MEDICINE OR DEVICE? - REGISTRATION ISSUES FOR 1990S
   Medical Device Technology 1990: 1 p20-25

7. VandenBurg MJ and Dews IM
   INCOME GENERATION FROM CLINICAL RESEARCH
   Hospimeda 1990: 8 p16-18

8. VandenBurg MJ and Dews IM
   'CLINICAL TRIALS UNIT - REVENUE GENERATION FOR THE CARDIOLOGY DEPARTMENT'
   Cardiology Management 1990: 4 (1) p2-3

9. VandenBurg MJ
   'INFORMED CONSENT'
   British Medical Journal 1991: 303 (6810) p1138

10. VandenBurg MJ and Nutley PG
    'GOOD CLINICAL PRACTICE: THE EFFECTS ON INVESTIGATORS IN HOSPITALS'
    Hospimeda 1991: 9 (6) p54-56

11. Dews IM and VandenBurg MJ
    'PREVENTING FRAUD'
    British Medical Journal 1991: 302 (6781) p907

12. VandenBurg MJ
    'DRUG RESEARCH RULES DEMAND SERIOUS STUDY'
    Hospital Doctor 1991: 111 (20) p21

13. Allen ME and VandenBurg MJ
    'GOOD CLINICAL PRACTICE: RULES, REGULATIONS AND THEIR IMPACT ON THE INVESTIGATOR'
14. Allen ME and VandenBurg MJ
   'GOOD CLINICAL PRACTICE IN EUROPE'
   Applied Clinical Trials 1992: 1 (1) p32-35

15. VandenBurg MJ and Brown J
   'DRUG SAFETY NEEDS GP SURVEILLANCE'
   General Practitioner 1992: p64

16. VandenBurg MJ, Davis M and Neal H
   'THE PHARMACEUTICAL INDUSTRY AND CONTRACT RESEARCH ORGANISATIONS'
   Fraud and Misconduct in Medical Research
   Published by BMJ Publishing Group

17. VandenBurg MJ
   'GCP DIFFERENCES BETWEEN NORTHERN AND SOUTHERN EUROPE'
   Applied Clinical Trials 1993: 2 p42-48

18. VandenBurg MJ and Allen ME
   'GOOD CLINICAL PRACTICE - A QUESTION OF BALANCE'
   British Journal of Clinical Pharmacology 1994: 37

19. VandenBurg MJ and Dews IM
   ‘CAREERS IN CONTRACT CLINICAL RESEARCH (I - EUROPE)’
   Discovering New Medicines: 1994: p186
   Published by John Wiley & Sons Ltd.

20. VandenBurg MJ
   ‘POSTMARKETING SURVEILLANCE - IS NOT USED TO PROMOTE PRODUCTS’

21. VandenBurg MJ and Dews IM
   “LETTER TO THE EDITOR”

22. VandenBurg MJ
   ‘GOOD CLINICAL PRACTICE IN NON-PHARMACEUTICAL RESEARCH’
   Good Clinical Practice Journal, Vol 8, No 2, p5-6, February 2001

23. VandenBurg MJ
   ‘ENSURING COMPLIANCE WITH GCP IN NON-PHARMACEUTICAL INDUSTRY-SPONSORED RESEARCH’
   Good Clinical Practice Journal, Vol 8, No 4, p21-24, April 2001

24. VandenBurg MJ
   ‘Proud To Be A Pharmaceutical Physician’
   Pharmaceutical Physician, Vol 12, no 1, p16-17, June 2001

25. VandenBurg MJ
   ‘GLOBALISATION 2002’
   The Regulatory Affairs Journal, Vol 13, no 1, p3, January 2002

26. VandenBurg MJ
   ‘Why Can’t The FDA Rule The World?’
   Scrip Magazine, p31, March 2002

27. VandenBurg MJ, Patel P
   Brookwood Medical Publications Ltd, 2002
   ‘Dilemmas And Solutions In Global Drug Development’
28. VandenBurg MJ
GMC Today.
Response to article entitled ‘Prescribing tomorrow’ ........ November/December 2009

B. Presentations to Learned Societies

‘METHODS OF ASSESSING PAIN IN CLINICAL TRIALS’
Medical Research Society 1984
Clinical Science 1984: 66 p78p

2. VandenBurg MJ, Hounslow NJ, Tamrazians S and Wiseman WT
‘DIFFICULTIES OF A VISUAL ANALOGUE SCALE IN THE ASSESSMENT OF ANGINA’
British Journal of Clinical Pharmacology 1987: 23

3. Hounslow NJ, Tamrazians S, Wiseman WT, Mann S and VandenBurg MJ
‘USE OF A VISUAL ANALOGUE METER’
British Journal of Clinical Pharmacology 1987: 23

4. VandenBurg MJ, Mackay EM and August R
‘THE PRACTICAL DIFFICULTIES OF CONDUCTING PAN EUROPEAN TRIALS’

C. Presentations to Congresses and Symposia

‘DOES IT MATTER HOW PREVIOUS VISUAL ANALOGUE SCALES ARE USED IN CLINICAL TRIALS?’
Published by Rheumatology Service, Hasharon Hospital, Israel 1984, Edited by Israel Machtey.

‘PAIN ASSESSMENT IN THE ELDERLY PATIENT’
9th International Congress of Physical Medicine and Rehabilitation, Israel, 1984: p256

3. Cook J, Wight LJ and VandenBurg MJ
‘NEW DRUG APPLICATION TO PRODUCT LICENCE APPLICATION’
7th International Conference on Pharmaceutical Medicine, Madrid 1990
Abstract 12-11 p49

‘THE UK SICKNESS IMPACT PROFILE (SIP) IN CARDIOVASCULAR DISEASE’
7th International Conference on Pharmaceutical Medicine, Madrid 1990
Abstract 12-12 p50

5. Potter CE, VandenBurg MJ and Wight LJ
‘THE VALUE OF DOING A SCIENTIFIC LARGE MULTI CENTRE PHASE IV PROGRAMME’
7th International Conference on Pharmaceutical Medicine, Madrid 1990
Abstract 12-13 p51

‘PROBLEMS IN DEVELOPING A PORTABLE UNIVERSAL DOUBLE-ENTRY CLINICAL TRIALS DATABASE: A POSSIBLE SOLUTION USING SAS’
7th International Conference on Pharmaceutical Medicine, Madrid 1990
Abstract 23-4 p101
7. VandenBurg MJ and Dews IM
   'EUROPEAN GCP - FACT OR FICTION'
   Controlled Release Society Workshop - Regulatory Affairs Concerning Controlled Release Systems

8. 'INTERNATIONAL UNITY OF STANDARDS AN EARLY GOAL FOR EUROPEAN GOOD CLINICAL PRACTICE' (Report by Nick Landon for BrAPP)
   BrAPP News 1991: 3 (1) p32-38

9. VandenBurg MJ
   Regulatory Affairs: 'STATUS OF EUROPEAN REGULATORY UNIFICATION'
   20th International Symposium on Controlled Release of Bioactive Materials 1993: Washington D.C., USA

10. VandenBurg MJ
   BrAPP Symposium a success
   Association update August 1998

D. Courses

1. VandenBurg MJ
   'ORGANISING CLINICAL TRIALS WITH SPECIAL EMPHASIS ON THE COLLECTION OF LABORATORY DATA'
   Clinical Trials and Laboratory Data Symposium, London 1983 organised by Tymshare U K and Jean Shanks Pathology Services

2. VandenBurg MJ
   'GOOD CLINICAL PRACTICE'
   University of Wales Institute of Science and Technology, postgraduate course in pharmaceutical medicine 1987-88.

3. VandenBurg MJ
   'GCP IN SOUTHERN EUROPE'
   Astra Digest 1991: 1 p14-15

4. VandenBurg MJ
   'THE EFFECTS OF EUROPEAN GCP ON THE PHARMACEUTICAL PHYSICIAN'
   Faculty of Pharmaceutical Medicine Annual General Meeting 1991

5. VandenBurg MJ
   'GCP EDUCATION FOR INVESTIGATORS'
   Astra International Medical Services GCP Conference 1991

6. VandenBurg MJ
   'PRACTICAL EXPERIENCE FROM IMPLEMENTING GCP IN EUROPE'
   Astra International Medical Services GCP Conference 1991

7. VandenBurg MJ and Morrison P
   'WHAT DOES A CRO NEED AND EXPECT FROM ITS CLIENTS?'
   IBC - Contract Research Organisations and How to Manage Them 1991

8. VandenBurg MJ
   'ESTABLISHING THE RESOURCES OF TRAINED INVESTIGATORS'
   BrAPP Symposium - Resources for Clinical Research: Current Issues 1992

9. VandenBurg MJ
   'STRATEGIC ISSUES IN DRUG DEVELOPMENT'
   BIOS Conferences - Clinical Trials & Drug Registration Data "Quality versus Quantity", London April 1992
10. Glover D
   'GOOD CLINICAL PRACTICE IN EUROPE - INVESTIGATOR HANDBOOK'

11. VandenBurg MJ
    'POST MARKETING SURVEILLANCE'
    Medical Forum - Sponsored by Glaxo Laboratories Ltd, London, April 1992

12. VandenBurg MJ
    'INDUSTRY AND INVESTIGATORS TO SHARE THE BURDEN OF INTRODUCING GCP'
    BrAPP Symposium: Resources for Clinical Research, February 1992
    Pharmaceutical Physician 1992: 4 (3) p30

13. VandenBurg MJ
    'NEW EEC DRUG REGISTRATION REGULATIONS'
    2nd Hospital Pharmacy Symposium - Scientific Program. Sponsored by CILAG, Spain, June 1992.

14. VandenBurg MJ
    'AN INDEPENDENT CLINICAL EXPERT'S VIEW'
    From Mouse to Man - Regulatory Strategies for Clinical Development
    The British Institute of Regulatory Affairs Symposium, July 1992

15. VandenBurg MJ
    'THE INVESTIGATOR'S RESPONSIBILITIES: EUROPEAN GUIDELINES'
    Good Clinical Research Practice. Sponsored by British Postgraduate Medical Federation, November 1992

16. VandenBurg MJ
    'WHAT DIFFERENT CROs NEED: CLINICAL'
    3rd International Conference on Contract Research Organisations: How to Manage Them
    IBC Technical Services, Nice 1992

17. VandenBurg MJ
    'HARMONISATION OF GCPs - COMPARISONS: EUROPE/USA/JAPAN'
    7th Annual Symposium on Good Clinical Practice in Europe. IBC Technical Services Conference Milan 1993

18. VandenBurg MJ
    'OPTIONS FOR REDUCING TIMESCALES'

19. VandenBurg MJ
    'HISTORY OF GCP IN EUROPE AND THE CURRENT STATUS OF THE LEGALITY OF GCP AT A EUROPEAN AND
    NATIONAL LEVEL'
    'European Clinical Research Monitors', Merck Sharp & Dohme, Stockholm 1993

20. VandenBurg MJ
    'COMPARISON OF EUROPEAN GCPs AND FDA GCPs'
    'European Clinical Research Monitors', Merck Sharp & Dohme, Stockholm 1993

21. VandenBurg MJ
    'GCP IN EUROPE: CONFERENCE REPORT'
    NEWS Update, Applied Clinical Trials 1993: (2) 7 p8-12

22. VandenBurg MJ
    'THE EUROPEAN EXPERT REPORT: THE CLINICAL EXPERT REPORT AS AN EXAMPLE'
    DDR Workshop. Sandoz Pharmaceuticals, Switzerland 1993
23. VandenBurg MJ
'USING AN NDA TO CONSTRUCT AND EC APPLICATION'
DDR Workshop. Sandoz Pharmaceuticals, Switzerland 1993

24. VandenBurg MJ
'FRUAD'
4th International Conference on Contract Research Organisations. 'The Changing Role of CROs in the 90s'. IBC Tehnical Services, Germany 1993

25. VandenBurg MJ
'UNDERTAKING THE TRIALS; PROVING THERAPEUTIC EQUIVALENCE'
Generic Medicines. Henry Stewart Conferences, London 1993

26. VandenBurg MJ
'REGULATORY ASPECTS OF DATA MANAGEMENT: FDA AND EEC ACCEPTANCE OF ELECTRONIC DATA'

27. Dews IM and VandenBurg MJ
'GCP MANAGEMENT OF A CLINICAL TRIALS UNIT'

28. VandenBurg MJ
'INVESTIGATORS AND CROs: ESSENTIAL ELEMENTS OF CREATING A GOOD WORKING RELATIONSHIP'
'Interactions Between Investigators, Sponsors and CROs in Europe: Sharing Clinical Trial Experience to Assure Quality'. Applied Clinical Trials, Switzerland 1994

29. Mascaro J, VandenBurg MJ and Weiner J
‘GCP 1995 - GOOD CLINICAL (RESEARCH) PRACTICES - HISTORICAL ORIGINS, CURRENT PRACTICES, QUALITY ASSURANCE, AUDIT AND THE DETECTION AND PREVENTION OF QUESTIONABLE PRACTICES’
Geneva Clinical Research Forum, December 1994

30. VandenBurg MJ
‘FDA INSPECTIONS IN EUROPE’
9th Annual Symposium on Good Clinical Practice in Europe, London, June 1995

31. VandenBurg MJ
‘THE IMPORTANCE OF GCP TO GENERIC MEDICINES’

32. VandenBurg MJ
‘INTEGRATED VALIDATION OF DATA’
Einladung zum Symposium des BVMA, Munich, November 1994

33. VandenBurg MJ
‘INTRODUCTION TO GCP’
‘COMPARING FDA WITH EUROPEAN GUIDELINES’
‘PREPARING FOR AN FDA AUDIT’
MSD European Medical Directors, Greece, June 1994
XVI. ISOSORBIDE MONONITRATE IN HEART FAILURE

A. Publications

1. Stephens JD, Marks CE, Woodings D, VandenBurg MJ
   'ACUTE AND CHRONIC USE OF ISOSORBIDE-5-MONONITRATE IN PATIENTS WITH HEART FAILURE'
   Cardiology 1987: 1 p69-71

   'DOSE-RANGING STUDY OF ISOSORBIDE-5-MONONITRATE IN CHRONIC CONGESTIVE HEART FAILURE TREATED WITH DIURETICS AND ANGIOTENSIN-CONVERTING ENZYME INHIBITOR'

B. Presentations to Learned Societies

   'A ONE MONTH COMPARISON OF ORAL ISOSORBIDE-5-MONONITRATE AND DIGOXIN IN CHRONIC STABLE HEART FAILURE'
   The Medical Research Society 1985
   Clinical Science 1986: 70 p8-9

2. Stephens JD, Marks CE, Tamrazians S, Woodings D and VandenBurg MJ
   'AN ACUTE DOSE-FINDING AND EFFICACY STUDY OF ISOSORBIDE-5-MONONITRATE IN CHRONIC STABLE HEART FAILURE'
   The British Pharmacological Society 1985
   British Journal of Clinical Pharmacology 1986: 21 p576

   'EFFICACY OF ISOSORBIDE-5-MONONITRATE (ISS5MN) IN PATIENTS TREATED WITH DIURETICS AND ENALAPRIL'
   The Medical Research Society Meeting 1987
   Clinical Science 1987: 72 p10

4. VandenBurg MJ, Marks CE, Woodings D and Stephens JD
   'LACK OF TOLERANCE TO ORAL ISOSORBIDE-5-MONONITRATE AFTER FOUR WEEKS’ THERAPY'
   Abstracts Book #1101

5. Stephens JD, Marks CE, Debbas N, Dews IM, Bahn A, VandenBurg MJ
   'ADDITION OF ISOSORBIDE-5-MONONITRATE (ISS5MN) TO ENALAPRIL IN RESISTANT HEART FAILURE'
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy 1987: 1 p293

6. Woodings D, Stephens JD, Marchant B, Dews IM, Debbas N, Marks CE and VandenBurg MJ
   'THE CHRONIC USE OF A MONONITRATE WITH ENALAPRIL IN HEART FAILURE'
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy 1987: 1 p304

   'A COMPARATIVE STUDY OF A NEW WIRELESS CONTINUOUS CARDIORESPIRATORY MONITOR FOR THE DIAGNOSIS AND MANAGEMENT OF PATIENTS WITH CONGESTIVE HEART FAILURE AT HOME'
'THE USE OF A NEW CONTINUOUS WIRELESS CARDIORESPIRATORY TELEMONITORING SYSTEM BY ELDERLY PATIENTS AT HOME'
_Presented at TeleMed 2001, 7 Suppl 1:76-7_

9. Simon de Lusignan, Anne Althans, Sally Wells, Paul Johnson, VandenBurg MJ and Jan Robinson
'A PILOT STUDY OF RADIOTELEMETRY FOR CONTINUOUS CARDIOPULMONARY MONITORING OF PATIENTS AT HOME'
C. Presentations at Congresses and Symposia

1. Stephens JD, Marks CE, Woodings D and VandenBurg MJ
   'ACUTE AND CHRONIC USE OF ISOSORBIDE-5-MONONITRATE IN PATIENTS WITH HEART FAILURE'
   Mononitrates First International Symposium 1986: organised by Schwartz

2. Stephens JD, Marks CE, Woodings D and VandenBurg MJ
   'PLASMA CONCENTRATION OF ISOSORBIDE-5-MONONITRATE AND HAEMODYNAMIC RESPONSE'
   Nitrates '87 An International Symposium, Venice 1987
   European Heart Journal 1987: 8 p71

   'DOSE RANGING STUDY OF ISOSORBIDE-5-MONONITRATE (IS5MN) IN PATIENTS WITH HEART FAILURE TREATED WITH DIURETICS AND ACE INHIBITORS'
   Satellite Symposium on Advances in the Clinical Practice of Nitrate Therapy, Montreux 1987: Abstracts Book p8

   'DOSE RANGING STUDY OF ISOSORBIDE-5-MONONITRATE ADDED TO DIURETICS AND ENALAPRIL IN HEART FAILURE'
   First International Symposium on Heart Failure - Mechanisms and Management, Jerusalem 1989: Abstracts Book #122

5. Woodings D, Stephens JD, Marchant B, Dews IM, Debbas N, Marks CE and VandenBurg MJ
   'CHRONIC USE OF ISOSORBIDE-5-MONONITRATE WITH DIURETICS AND ENALAPRIL IN HEART FAILURE'
   First International Symposium on Heart Failure - Mechanisms and Management, Jerusalem 1989: Abstract Book #126

   'EFFECTS OF ISOSORBIDE-5-MONONITRATE ON HAEMODYNAMICS AND EXERCISE TOLERANCE IN PATIENTS WITH HEART FAILURE: COMPARISONS WITH DIGOXIN AND PLACEBO'
   First International Symposium on Heart Failure - Mechanisms and Management, Jerusalem 1989: Abstract Book #455

31
XVII. QUALITY OF LIFE

A. Publications

1. VandenBurg MJ
   ‘MEASURING THE QUALITY OF LIFE OF PATIENTS WITH ANGINA’
   CMR Workshop Series "Quality of life: Assessment and Application"
   CIBA Foundation 1987: p267-277
   Published by MTP Press, Edited by Walker SR and Rosser RM
   Quality of Life Assessment: Key Issues in the 1990s
   Published by Kluwer Academic Publishers, Edited by Walker SR and Rosser RM

2. Salek MS and VandenBurg MJ
   ‘MEASURING THE QUALITY OF LIFE IN ANGINA PECTORIS’
   Journal for Drug Therapy and Research 1988: 5 p186-190

B. Presentations to Learned Societies

   ‘IS PATIENT RATED HEALTH AND QUALITY OF LIFE USEFUL IN THE CLINICAL ASSESSMENT OF ANGINA PECTORIS?’
   X World Congress of Cardiology, Washington D.C., 1986
   Abstracts book #629

2. Shayegan-Salek MS, Luscombe DK, Walker SR, Pugh S and VandenBurg MJ
   ‘QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH ANGINA USING THE SICKNESS IMPACT PROFILE (SIP)’
   The British Pharmacological Society 1987

   ‘QUALITY OF LIFE OF PATIENTS WITH ANGINA TREATED WITH NITROGLYCERIN (GTN) SPRAY’
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy, 1987: 1 p242

   ‘COMPARING HEALTH PROFILES IN PATIENTS WITH ANGINA’
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy, 1987: 1 p284

5. Salek MS, Luscombe DK, Walker SR and VandenBurg MJ
   ‘QUALITY OF LIFE IN CARDIOVASCULAR PATIENTS’
   Third French congress of clinical pharmacy
   16th European symposium on clinical pharmacy 1987: p93 Abstract Book

   ‘IMPORTANCE OF PATIENT INVOLVEMENT IN CLINICAL DECISION MAKING’
   Third French congress of clinical pharmacy
   16th European symposium on clinical pharmacy 1987

   ‘CARDIOVASCULAR DISEASE AND QUALITY OF LIFE’
   British Pharmacological Society, Royal College of Surgeons in Ireland 1988
   British Journal of Clinical Pharmacology 1988: 26 p628

32
8. Shayegan-Salek MS, Luscombe DK, Walker SR and VandenBurg MJ
'QUALITY OF LIFE ASSESSMENT IN ANGINA PATIENTS'
European Society of Clinical Pharmacy
15th European symposium on clinical pharmacy, Lisbon 1986: p19 Abstract Book

DOES BENDROFLUAZIDE IMPAIR THE QUALITY OF LIFE OF ELDERLY HYPERTENSIVES? RESULTS OF A RANDOMISED CONTROLLED TRIAL.
British Geriatrics Society, Pharmacology and Therapeutics Meeting 1990

C. Presentations at Congresses and Symposia

1. Salek MS, Luscombe DK, Walker SR and VandenBurg MJ
'QUALITY OF LIFE STUDY IN ANGINA PATIENTS'

2. VandenBurg MJ
'MEASURING QUALITY OF LIFE IN ANGINA'
CMR Symposium on Quality of Life: Assessment and Application 1987
Centre for Medicines Research News 1987: 5

3. VandenBurg MJ
'TWO HEALTH STATUS QUESTIONNAIRES IN THE ASSESSMENT OF ANGINA'
International symposium under the auspices of the International Federation of Associations of Pharmaceutical Physicians organised by the Dutch Association of Pharmaceutical Physicians.
Quality of Life ... a new branch on the decision tree.
The Hague 1987
XVIII. BRL 34915

A. Publications

   'POTASSIUM CHANNEL ACTIVATORS LOWER BLOOD PRESSURE: AN INITIAL STUDY OF BRL 34915 IN HYPERTENSIVE PATIENTS'
   Journal of Hypertension 1986: 4 pS166-S167

   'POTASSIUM CHANNEL ACTIVATORS: ANTIHYPERTENSIVE ACTIVITY AND ADVERSE EFFECT PROFILE OF BRL 34915'
   Journal of Hypertension 1987: 5 pS193-S195

B. Presentations to Learned Societies

   'POTASSIUM CHANNEL ACTIVATORS: HYPOTENSIVE ACTIVITY AND ADVERSE EFFECT PROFILE THE FIRST STUDY WITH BRL 34915'
   Third European Meeting on Hypertension, Milan 1987
   SCRIP 1987: p1226

   'POTASSIUM CHANNEL ACTIVATORS: ANTIHYPERTENSIVE ACTIVITY AND EFFECTS ON RESTING SURFACE ECG: A STUDY WITH BRL 34915'
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy 1987: 1 p276

   'BRL 34915 A NOVEL POTASSIUM CHANNEL ACTIVATOR: DURATION OF ANTIHYPERTENSIVE ACTION'
   Second Cardiovascular Pharmacotherapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy 1987: 1 p299

   'POTASSIUM CHANNEL ACTIVATORS LOWER BLOOD PRESSURE: AN INITIAL STUDY OF BRL 34915 IN HYPERTENSIVE patients'
   ISH Heidelberg 1986: s166-167
IXX. ANGINA STUDIES

A. Publications

1. VandenBurg MJ, Griffiths GK and Brandman S
   'SUBLINGUAL NITROGLYCERIN OR SPRAY IN THE TREATMENT OF ANGINA'
   British Journal of Clinical Practice 1986: 40 p524-527

2. Wight LJ, Potter CE, VandenBurg MJ and Brandman S
   'EXPERIENCE WITH NITROLINGUAL SPRAY IN GENERAL PRACTICE'
   British Journal of Clinical Practice 1990: 44
   Referenced in: 'Glyceryl Trinitrate for Angina: Tablet or Spray?'
   Drug and Therapeutics Bulletin (Published by Which?) 1992: 30 p93-96 (at p95)

3. Foale RA and VandenBurg MJ
   'SUSTAINED-RELEASE VERAPAMIL AND NIFEDIPINE IN EXERCISE-INDUCED ANGINA PECTORIS'
   European Heart Journal 1992: 13 p256-260

   'A LARGE SCALE COMPARATIVE STUDY IN GENERAL PRACTICE WITH NITROGLYCERIN SPRAY AND TABLET FORMULATIONS IN ELDERLY PATIENTS WITH ANGINA PECTORIS'

5. VandenBurg MJ
   NITRATE SPRAY IN ANGINA CARE

B. Presentations to Learned Societies

   'EFFICACY OF METOPROLOL OROS COMPARED WITH CONVENTIONAL METOPROLOL IN EXTENDING THE EXERCISE TOLERANCE OF PATIENTS WITH ANGINA PECTORIS'
   British Pharmacological Society 1987

2. Wight LJ, VandenBurg MJ and Griffiths G
   'THE EFFECT OF AGE ON EFFICACY OF SUBLINGUAL NITROGLYCERIN IN ANGINA'
   Second Cardiovascular Pharmacotberapy International Symposium, San Francisco 1987
   Cardiovascular Drugs and Therapy 1987: 1 p302

   'A COMPARISON OF THE EFFECT OF CARVEDILOL AND NIFEDIPINE ON THE EXERCISE CAPACITY OF PATIENTS WITH ISCHAEMIC HEART DISEASE'
   British Pharmacological Society 1988

   'INFORMATION RECALL IN PATIENTS RECEIVING NITROGLYCERIN'
   Medical Research Society 1987
   Clinical Science 1987: 72 p77
'SUSTAINED RELEASE VERAPAMIL IN CHRONIC STABLE ANGINA PECTORIS: A MULTICENTRE RANDOMISED DOUBLE-BLIND CROSSOVER DESIGN TRIAL VERSUS PLACEBO'
British Pharmacological Society 1990
British Journal of Clinical Pharmacology 1990: 30 p340-341

6. Foale RA and Vandenburg MJ
'SUSTAINED-RELEASE VERAPAMIL AND NIFEDIPINE IN EXERCISE INDUCED ANGINA PECTORIS'
British Pharmacological Society 1990
British Journal of Clinical Pharmacology 1990: 30 p313

C. Presentations at Congresses and Symposia

1. Vandenburg MJ, Wight LJ and Potter CE
'THE EFFICACY AND TOLERABILITY OF SUBLINGUAL NITROGLYCERIN SPRAY IN ELDERLY PATIENTS WITH ANGINA PECTORIS'
International Union of Angiology 15th World Congress: Rome 1989

2. Wight LJ, Potter CE and Vandenburg MJ
'INVESTIGATION INTO THE PROPHYLACTIC BENEFIT OF NITROGLYCERIN SPRAY IN PATIENTS WITH ANGINA'
International Union of Angiology 15th World Congress: Rome 1989

3. Potter CE, Vandenburg MJ and Wight LJ
'EFFICACY AND TOLERABILITY OF NITROGLYCERIN TABLETS VERSUS SPRAY IN ANGINA PECTORIS'
International Union of Angiology 15th World Congress: Rome 1989
XX. PHARMACOKINETICS

A. Publications

Desche P
'THE PHARMACOKINETICS OF PERINDOPRIL AND ITS EFFECTS ON SERUM ANGIOTENSIN CONVERTING ENZYME
ACTIVITY IN HYPERTENSIVE PATIENTS WITH CHRONIC RENAL FAILURE’

'DIGOXIN PHARMACOKINETICS AND PERINDOPRIL IN HEART FAILURE PATIENTS’
British Journal of Clinical Pharmacology 1993: 33 p146-149

B. Presentations to Learned Societies

1. VandenBurg MJ, Mackay EM, Laher MS, Donohoe J, Doyle GD Kelly JG, Glover DR and Smith L
'THE CHRONIC PHARMACOKINETICS OF DILEVALOL IN RENAL IMPAIRMENT’
British Pharmacological Society 1990
British Journal of Clinical Pharmacology 1990: 29 p615

LACK OF PHARMACOKINETIC INTERACTION BETWEEN DIGOXIN AND PERINDOPRIL AFTER CHRONIC
TREATMENT OF PATIENTS WITH CONGESTIVE HEART FAILURE
Nineteenth Annual American College of Clinical Pharmacology Meeting 1990
The Journal of Clinical Pharmacology 1990: 30 p858

C. Presentations at Congresses and Symposia

1. VandenBurg MJ
'EUROPEAN GCP - FACT OR FICTION’
Controlled Release Society Workshop - Regulatory Affairs Concerning Controlled Release Systems,
Amsterdam 1991

2. VandenBurg MJ
'MOVING THE GOAL POSTS IN EUROPEAN BIOEQUIVALENCE DATA’
Controlled Release Society Workshop - Regulatory Affairs Concerning Controlled Release Systems,
Amsterdam 1991

'INFLUENCE OF PERINDOPRIL ON DIGOXIN LEVELS IN CONGESTIVE HEART FAILURE PATIENTS’
Abstracts - Second International Symposium on ACE Inhibition 1991: P-23
XXII. GENERAL MEDICAL TOPICS

A. A Controversial Career

1. VandenBurg MJ  
   BMJ CAREERS  
   8 August 2009

B. Presentations to Learned Societies

1. VandenBurg MJ  
   ‘THE METHODOLOGY OF A SURVEY OF THE TREATMENT OF BLEEDING EPISODES IN HAEMOPHILIC PATIENTS WITH INHIBITORS’  
   XVth Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, June 1995
XXIII. ADVISORY BOARDS AND ACADEMIC REVIEWS

1. Member of the Editorial Advisory Board, Applied Clinical Trials
2. Reviewer of British Journal of Clinical Pharmacology
3. Reviewer of Journal of Human Hypertension
4. Editorial Board of Journal of Good Clinical Practice
5. Editor in Chief of Solutions and Dilemmas in Global Drug Development
XXIV. 1997 EDITORIAL ARTICLES

A. *Scrip*

1. VandenBurg MJ
   ‘OPINIONS, FRIENDS AND EXPERIENCE’
   *Scrip Magazine*, April 1997: p14

2. VandenBurg MJ
   ‘EUROPEAN CLINICAL TRIALS - TAKING A UNITED APPROACH’
   *Scrip Magazine*, May 1997: p22-23

3. VandenBurg MJ
   ‘CHANGES AND CHANCES IN THE CRO SECTOR’
   *Scrip Magazine*, July/August 1997: p21-23

4. VandenBurg MJ
   ‘RAISING THE STANDARDS OF CLINICAL PRACTICE IN THE UK’

5. VandenBurg MJ
   “PHARMACEUTICAL PERSONNEL UNDER PRESSURE”
   *Scrip Magazine*, November 1997: p24-25

B. *Applied Clinical Trials*

1. VandenBurg MJ and Takahashi Y
   ‘IMPLEMENTING THE ICH GCP GUIDELINE IN JAPAN’
   *Applied Clinical Trials*, 1997: 8 p22-28

2. VandenBurg MJ and Wight LJ
   ‘ARE CROs GETTING TOO BIG?’
   *Applied Clinical Trials*, 1997: 6 p86-87

C. *European Pharmaceutical Contractor*

1. VandenBurg MJ
   ‘JAPANESE CULTURE, PHILOSOPHIES AND SOME IMPLICATIONS’
   *European Pharmaceutical Contractor*, May 1997, p130-132

2. VandenBurg MJ
   ‘THE JAPANESE PHARMACEUTICAL PERSONALITY’
   *European Pharmaceutical Contractor*, August 1997, p54-56

D. *Pharmaceutical Times*

1. ‘FROM PORTACABIN TO GLOBAL FORCE ...’
   *Pharmaceutical Times*, November, 1996, p14-16

E. *Pharmaceutical Visions*

1. ‘A MAN OF PRINCIPLES’
F. **Ham & High**

1. VandenBurg MJ  
   ‘SILVERSTONE, DAYTONA, LE MANS - AND THE SCHOOL RUN’  
   *Ham & High, No. 7116, 27th June, 1997*

2. VandenBurg MJ  
   Jean Wanted My Baby To Star In Hollywood Movie ...  
   *Ham & High, 4 February 2010*

3. VandenBurg MJ  
   The Day I Shared A Hangover With Peter Cook ...  
   *Ham & High, 11 February 2010*

G. **Sales Director**

1. VandenBurg MJ  
   Grace Under pressure ...  
   *November 1998*

H. **Training Officer**

1. VandenBurg MJ  
   Giving Managers the tools to manage stress at work ...  
   *December 1998*

I. **Pharmaceutical Marketing**

1. VandenBurg MJ  
   Marriage Guidance for Medical & Marketing .......  
   *June 1998*

J. **GMC Today**

1. VandenBurg MJ  
   Response to article entitled ‘Prescribing tomorrow’ .......  
   *November/December 2009*

K. **R&D Directions**

1. VandenBurg MJ  
   Smashing the barriers........  
   *July/August 1998*
L. Miscellaneous

1. VandenBurg MJ
   Let's learn from Diana
   *Hospital Doctor, January 1998*

2. VandenBurg MJ
   Proud to be a Pharmaceutical Physician
   *Pharmaceutical Physician, June 2001*

3. VandenBurg MJ
   I'm dreaming of .......
   *January 2002*
XXV. PERSONAL DEVELOPMENT

A. **Publications**

1. VandenBurg MJ
   ‘PERSONAL DEVELOPMENT TRAINING’
   *Pharmaceutical Times, September 1994, p26*

2. VandenBurg MJ
   ‘SELF CONFIDENCE FOR SUCCESS’
   *Pharmaceutical Marketing, September 1994: p41*

3. VandenBurg MJ
   ‘CONSULTANCIES - BITING THE BULLET - ROSTRUM’
   *Pharmaceutical Visions, 1994: p89*

B. **Presentations**

See Positive Under Pressure CV
The Royal Society of Medicine
The Royal College of General Practitioners
The Royal College of Psychiatrists
Royal Defence Medical College
The Royal Navy
HM Treasury
University of Wales
Association of Accounting Techniques
Pfizer
Pharmacia
International Business Communications
60 Positive Under Pressure seminars have been performed for local GP tutors as part of refresher courses, study days or weekly meetings
10 Positive Under Pressure Seminars have been performed for Human Resources Departments in the Healthcare sector
5 seminars have been performed for NHS Trusts
University of Portsmouth

1. VandenBurg MJ
   ‘PROJECT TEAM MEETINGS’

2. VandenBurg MJ and Lindenfield G
   ‘MAXIMISING YOUR POTENTIAL - POSITIVE UNDER PRESSURE’
   ACRPI - Keeping up with the Changes, Eastbourne, March 1995

3. VandenBurg MJ and Lindenfield G
   ‘MAXIMISING YOUR POTENTIAL - POSITIVE UNDER PRESSURE’
   ACRPI - Clinical Research Focus, May 1995, pSvii
C. Presentations to Congresses and Symposia

1. VandenBurg MJ, Lindenfield G and Hassan J  
   “WINNING AT THE CAREER GAME”  

D. Other Presentations

1. VandenBurg MJ and Lindenfield G  
   “POSITIVE UNDER PRESSURE”  
   Mosimann’s, London, October 1995

2. VandenBurg MJ and Dews IM  
   “POSITIVE UNDER PRESSURE”  
   Clinical Operations National Meeting, IBRD-ROSTRUM GLOBAL INC, California, USA, 20th September, 1996

3. VandenBurg MJ and Lindenfield G  
   “POSITIVE UNDER PRESSURE”  
   The Royal Society of Medicine, June 1997

4. VandenBurg MJ and Lindenfield G  
   “POSITIVE UNDER PRESSURE”  
   Pfizer Ltd., Kent, 17th & 18th June, 1997

5. VandenBurg MJ and Lindenfield G  
   “POSITIVE UNDER PRESSURE”  
   The Personal Development Show ‘97, Olympia, London, 29th June, 1997

6. VandenBurg MJ and Lindenfield G  
   “POSITIVE UNDER PRESSURE”  
   Impact Plus Limited, Teddington, Middlesex, 13th August, 1997
XXVI. SLEEP APNEA AND CARDIOVASCULAR MONITORING

A. Publications

B. Presentations

C. Presentations to Congresses and Symposia

D. Other Presentations
1. VandenBurg MJ
   ‘WOULD THIS TRIAL DESIGN BE ACCEPTABLE FOR A MEDICINE’ (April 2004)
   Rapid Response to:
   ‘Acupuncture For Chronic Headache In Primary Care: Large, Pragmatic, Randomised Trial’
   BMJ 2004; 328: 744-0

2. VandenBurg MJ
   ‘HOW DO PARENTS OF ADOLESCENTS AND CHILDREN MAKE SENSIBLE DECISIONS NOW?’ (19 April 2004)
   Rapid Response to:
   ‘Efficacy and safety of antidepressants for children and Adolescents’
   BMJ 2004; 328: 879-883

3. VandenBurg MJ
   ‘WHAT IS IT ABOUT ACADEMICS?’ (3 May 2004)
   Rapid Response to:
   ‘Squeezing academic research into a commercial straitjacket’
   BMJ 2004; 328: 1036

4. VandenBurg MJ
   ‘HIV 2 INFLUENCED THE EUROPEAN CUP!’ (1 August 2004)
   Rapid Response to:
   ‘Sex, sun, sea and STIs: sexually transmitted infections acquired on holiday’
   BMJ 2004; 329; 214-217

5. VandenBurg MJ
   ‘RISK OF SUICIDALITY WITH SSRIs – WHERE DO WE GO FROM HERE?’
   Rapid Response to:
   ‘Risk of suicidal behaviour in adults taking antidepressants’
   BMJ 2009; 339; b3066
XXVIII. MEDICO LEGAL ARTICLES

28a Prescription Medication – a forensic perspective
Pages 42 to 44.

28b Could the cure really be the cause
Published in Your Witness magazine, 2009.

28c Issues in forensic cases associated with SSRIs
July 2009

28d The dangers of inappropriate use of Propofol in the tragic demise of Michael Jackson
August 2009

28e Prescription Medication – A Forensic Perspective
August 2009

28f Stephen Gately – Fluid on the lungs – but why?
October 2009

28g Drug driving – time for a new fangled device or a sensible review of the law?
August 2010

28h When a condom is not enough
August 2010

28i What will happen to patients who drive after taking legalised cannabinoid sprays
September 2010